LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.
Saved in:
| Title: | LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome. |
|---|---|
| Authors: | Maloney MT; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Wang X; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Tenvie Therapeutics, South San Francisco, CA, 94080, USA., Ghosh R; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Andrews SV; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Maciuca R; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Masoud ST; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Agam M; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Tenvie Therapeutics, South San Francisco, CA, 94080, USA., Caprioli RM; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN, 37240, USA., Astarita G; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Bondar VV; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Chen J; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Chiu CL; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Davis SS; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Ho AC; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Nguyen HN; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Propson NE; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Reyzer ML; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN, 37240, USA., Davis OB; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Deen MC; Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada., Zhu S; Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada., Di Paolo G; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Vocadlo DJ; Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada., Estrada AA; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Tenvie Therapeutics, South San Francisco, CA, 94080, USA., de Vicente J; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Tenvie Therapeutics, South San Francisco, CA, 94080, USA., Lewcock JW; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Arguello A; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Suh JH; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Huntwork-Rodriguez S; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Henry AG; Denali Therapeutics Inc, 161 Oyster Point Blvd, South San Francisco, CA, 94080, USA. henry@dnli.com. |
| Source: | Molecular neurodegeneration [Mol Neurodegener] 2025 Aug 06; Vol. 20 (1), pp. 89. Date of Electronic Publication: 2025 Aug 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101266600 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1326 (Electronic) Linking ISSN: 17501326 NLM ISO Abbreviation: Mol Neurodegener Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1750-1326 |
|---|---|
| DOI: | 10.1186/s13024-025-00880-7 |
